Curriculum-Based Online and Live Activities

 


Course Director
Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia


Curriculum Description

Through this curriculum that comprises a web-based educational activity and on-site sessions at US medical facilities, we hope to provide clinicians with resources for offering state-of-the-art personalized care to their patients with myeloma. Join us in exploring the following topics and more:

  • The latest clinical data on novel agent classes and next-generation therapeutics in myeloma, including proteasome inhibitors, immunomodulatory drugs, immunotherapies, and epigenetic agents, among others
  • Tailoring care in newly-diagnosed myeloma—how do age, eligibility for stem-cell transplantation, high-risk features or comorbid illnesses, or need for maintenance therapy affect our choice of treatment?
  • Considerations for selecting individualized regimens for patients with relapsed/refractory myeloma, including those with early relapse or treatment-refractory disease
  • Best practices for managing treatment-related adverse events in patients with myeloma—what do we need to be vigilant of in patients receiving novel therapies?

Case scenarios of newly-diagnosed or relapsed/refractory patients with myeloma from community-based practice, which illustrate pragmatic concerns of daily patient care, will be incorporated as teaching tools and to stimulate interaction in the local live group setting.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists, advanced practice nurses, and other clinicians involved in the care of patients with multiple myeloma.